Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion
Aarti Drugs Ltd 路 Investor Presentation 路 04 Nov 2026, 3:17 am
Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion Aarti Drugs delivered robust Q2 FY27 performance, with total revenue rising 27% YoY to Rs 828.8 crore and net profit jumping 83% YoY to Rs 82.8 crore. EBITDA grew 63% YoY to Rs 137.9 crore, with margins expanding 370 bps YoY to a multi-year high of 16.6%, aided by higher realizations and backward integration at the Sayakha facility. Formulations and Specialty Chemicals drove broad-based growth. Ongoing brownfield expansions across anti-diabetic and anti-inflammatory segments remain on track to deepen penetration in regulated markets.
Original exchange filing (PDF)
More announcements from Aarti Drugs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company 路 16 Nov 2026
- Transcript of Q2&H1 FY27 Earning Conference call 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requireents) Regulations, 2015 路 06 Nov 2026
- Audio recording for conference call for Analyst and Investors 路 05 Nov 2026
- Press release on Financial results for Quarter and Half year ended September 2026 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
